Reunderstanding the classical prescription Banxia Xiexin Decoction: new perspectives from a comprehensive review of clinical research and pharmacological studies.

IF 5.3 3区医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE

Chinese Medicine Pub Date : 2025-03-18 DOI:10.1186/s13020-025-01087-0

Chang Liu, Pengwei Gao, Xiaoying Liu, Min Kuang, Haoran Xu, Yangming Wu, Wenjun Liu, Shengpeng Wang

{"title":"Reunderstanding the classical prescription Banxia Xiexin Decoction: new perspectives from a comprehensive review of clinical research and pharmacological studies.","authors":"Chang Liu, Pengwei Gao, Xiaoying Liu, Min Kuang, Haoran Xu, Yangming Wu, Wenjun Liu, Shengpeng Wang","doi":"10.1186/s13020-025-01087-0","DOIUrl":null,"url":null,"abstract":"<p><p>Classical prescriptions of Chinese medicine represent the crystallized wisdom of millennia of clinical practice, enduring as cornerstones of therapeutic intervention due to their demonstrated efficacy across generations. Their evolving role in modern healthcare systems reflects shifting disease patterns, scientific advancements, and global health priorities. Banxia Xiexin Decoction (BXD), formulated by Zhang Zhongjing in the Treatise on Febrile and Miscellaneous Diseases (Shanghanlun), is a time-honored classical prescription renowned for its therapeutic versatility in managing gastrointestinal disorders, both in China and internationally. Recent advancements in clinical research and pharmacological studies on BXD underscore the necessity for a comprehensive bibliometric analysis to summarize and elucidate its specific clinical benefits. Through an extensive literature review of publications from the Web of Science, PubMed, Scopus, and the China National Knowledge Infrastructure (CNKI) between 1997 and 2024, 11 major categories of clinical applications for BXD were identified, along with an analysis of the potential pharmacological mechanisms, such as chronic gastritis, functional dyspepsia, and inflammatory bowel disease. We believe this review will provide new insights into the understanding of clinical value of BXD and identify potential future perspectives for its research and development.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"39"},"PeriodicalIF":5.3000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921579/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13020-025-01087-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Classical prescriptions of Chinese medicine represent the crystallized wisdom of millennia of clinical practice, enduring as cornerstones of therapeutic intervention due to their demonstrated efficacy across generations. Their evolving role in modern healthcare systems reflects shifting disease patterns, scientific advancements, and global health priorities. Banxia Xiexin Decoction (BXD), formulated by Zhang Zhongjing in the Treatise on Febrile and Miscellaneous Diseases (Shanghanlun), is a time-honored classical prescription renowned for its therapeutic versatility in managing gastrointestinal disorders, both in China and internationally. Recent advancements in clinical research and pharmacological studies on BXD underscore the necessity for a comprehensive bibliometric analysis to summarize and elucidate its specific clinical benefits. Through an extensive literature review of publications from the Web of Science, PubMed, Scopus, and the China National Knowledge Infrastructure (CNKI) between 1997 and 2024, 11 major categories of clinical applications for BXD were identified, along with an analysis of the potential pharmacological mechanisms, such as chronic gastritis, functional dyspepsia, and inflammatory bowel disease. We believe this review will provide new insights into the understanding of clinical value of BXD and identify potential future perspectives for its research and development.

查看原文本刊更多论文

重新认识半夏泻心汤：从临床研究和药理研究的综合综述的新视角。

中医经典处方代表了数千年临床实践的结晶智慧，因其代代相传的疗效而成为治疗干预的基石。它们在现代卫生保健系统中不断演变的作用反映了疾病模式的转变、科学进步和全球卫生重点。半夏泻心汤（BXD）是由张仲景在《伤寒论》（《伤寒论》）中配制的一种历史悠久的经典方剂，以其治疗胃肠疾病的多效性而闻名于中国和国际。近年来BXD的临床研究和药理学研究的进展强调有必要进行全面的文献计量分析，以总结和阐明其具体的临床益处。通过对1997年至2024年间Web of Science、PubMed、Scopus和中国知网（CNKI）的出版物进行广泛的文献回顾，确定了BXD的11个主要临床应用类别，并分析了其潜在的药理机制，如慢性胃炎、功能性消化不良和炎症性肠病。我们相信这一综述将为BXD的临床价值的认识提供新的见解，并为其未来的研究和开发提供潜在的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-PHARMACOLOGY & PHARMACY

CiteScore

7.90

自引率

4.10%

发文量

133

审稿时长

31 weeks

期刊介绍： Chinese Medicine is an open access, online journal publishing evidence-based, scientifically justified, and ethical research into all aspects of Chinese medicine. Areas of interest include recent advances in herbal medicine, clinical nutrition, clinical diagnosis, acupuncture, pharmaceutics, biomedical sciences, epidemiology, education, informatics, sociology, and psychology that are relevant and significant to Chinese medicine. Examples of research approaches include biomedical experimentation, high-throughput technology, clinical trials, systematic reviews, meta-analysis, sampled surveys, simulation, data curation, statistics, omics, translational medicine, and integrative methodologies. Chinese Medicine is a credible channel to communicate unbiased scientific data, information, and knowledge in Chinese medicine among researchers, clinicians, academics, and students in Chinese medicine and other scientific disciplines of medicine.